Page last updated: 2024-08-17

prednisone and yttrium radioisotopes

prednisone has been researched along with yttrium radioisotopes in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (80.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hernandez, MC; Knox, SJ	1
Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O	1
Alinari, L; Baccarani, M; Bacci, F; Castellucci, P; de Vivo, A; Derenzini, E; Fanti, S; Farsad, M; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL	1
Dannaher, C; Greco, FA; Hainsworth, JD; Markus, TM; Rotman, R; Shipley, D; Spigel, DR; Thompson, D	1
Ansuinelli, M; Argnani, L; Bottelli, C; Broccoli, A; Cabras, MG; Casadei, B; Ciochetto, C; Gaidano, G; Gandolfi, L; Pellegrini, C; Stefoni, V; Zinzani, PL	1

Reviews

1 review(s) available for prednisone and yttrium radioisotopes

Article	Year
Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. International journal of radiation oncology, biology, physics, 2004, Aug-01, Volume: 59, Issue:5 Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Prednisone; Radiation-Sensitizing Agents; Radiobiology; Radioimmunotherapy; Vincristine; Yttrium Radioisotopes	2004

Article

Year

Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.

International journal of radiation oncology, biology, physics, 2004, Aug-01, Volume: 59, Issue:5

Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Prednisone; Radiation-Sensitizing Agents; Radiobiology; Radioimmunotherapy; Vincristine; Yttrium Radioisotopes

2004

Trials

2 trial(s) available for prednisone and yttrium radioisotopes

Article	Year
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Feasibility Studies; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prednisone; Prognosis; Prospective Studies; Radioimmunotherapy; Remission Induction; Thrombocytopenia; Treatment Outcome; Vincristine; Yttrium Radioisotopes	2008
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Prednisone; Radioimmunotherapy; Rituximab; Treatment Outcome; Vincristine; Yttrium Radioisotopes	2009

Article

Year

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4

Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Feasibility Studies; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prednisone; Prognosis; Prospective Studies; Radioimmunotherapy; Remission Induction; Thrombocytopenia; Treatment Outcome; Vincristine; Yttrium Radioisotopes

2008

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.

Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Prednisone; Radioimmunotherapy; Rituximab; Treatment Outcome; Vincristine; Yttrium Radioisotopes

2009

Other Studies

2 other study(ies) available for prednisone and yttrium radioisotopes

Article	Year
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia, 2007, Volume: 21, Issue:3 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes	2007
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results. Blood cancer journal, 2016, 05-13, Volume: 6 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Radioimmunotherapy; Rituximab; Survival Analysis; Treatment Outcome; Vincristine; Yttrium Radioisotopes	2016

Article

Year

Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.

Leukemia, 2007, Volume: 21, Issue:3

Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes

2007

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.

Blood cancer journal, 2016, 05-13, Volume: 6

Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Radioimmunotherapy; Rituximab; Survival Analysis; Treatment Outcome; Vincristine; Yttrium Radioisotopes

2016